Your browser doesn't support javascript.
loading
Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma.
Krabbe, Laura-Maria; Heitplatz, Barbara; Preuss, Sina; Hutchinson, Ryan C; Woldu, Solomon L; Singla, Nirmish; Boegemann, Martin; Wood, Christopher G; Karam, Jose A; Weizer, Alon Z; Raman, Jay D; Remzi, Mesut; Rioux-Leclercq, Nathalie; Haitel, Andrea; Rapoport, Leonid M; Glybochko, Peter V; Roscigno, Marco; Bolenz, Christian; Bensalah, Karim; Sagalowsky, Arthur I; Shariat, Shahrokh F; Lotan, Yair; Xylinas, Evanguelos; Margulis, Vitaly.
Afiliação
  • Krabbe LM; Department of Urology, University of Muenster Medical Center, Muenster, Germany; Department of Urology, University of Texas Medical Center, Dallas, Texas.
  • Heitplatz B; Department of Pathology, University of Muenster Medical Center, Muenster, Germany.
  • Preuss S; Department of Urology, University of Muenster Medical Center, Muenster, Germany.
  • Hutchinson RC; Department of Urology, University of Texas Medical Center, Dallas, Texas.
  • Woldu SL; Department of Urology, University of Texas Medical Center, Dallas, Texas.
  • Singla N; Department of Urology, University of Texas Medical Center, Dallas, Texas.
  • Boegemann M; Department of Urology, University of Muenster Medical Center, Muenster, Germany.
  • Wood CG; Department of Urology, M. D. Anderson Cancer Center, Houston, Texas.
  • Karam JA; Department of Urology, M. D. Anderson Cancer Center, Houston, Texas.
  • Weizer AZ; Department of Urology, University of Michigan Cancer Center, Ann Arbor, Michigan.
  • Raman JD; Division of Urology, Penn State Health Milton S.Hershey Medical Center, Hershey, Pennsylvania.
  • Remzi M; Department of Urology, Medical University Vienna, Vienna, Austria.
  • Rioux-Leclercq N; Department of Pathology, Centre Hospitalier Universitaire de Rennes, Rennes, France.
  • Haitel A; Department of Pathology, Medical University Vienna, Vienna, Austria.
  • Rapoport LM; Department of Uronephrology and Reproductive Health, Sechenov First Moscow State Medical University, Moscow, Russia.
  • Glybochko PV; Department of Uronephrology and Reproductive Health, Sechenov First Moscow State Medical University, Moscow, Russia.
  • Roscigno M; Department of Urology, Ospedali Riuniti of Bergamo, Bergamo, Italy.
  • Bolenz C; Department of Urology, University of Ulm, Ulm, Germany.
  • Bensalah K; Department of Urology, Centre Hospitalier Universitaire de Rennes, Rennes, France.
  • Sagalowsky AI; Department of Urology, University of Texas Medical Center, Dallas, Texas.
  • Shariat SF; Department of Urology, Medical University Vienna, Vienna, Austria.
  • Lotan Y; Department of Urology, University of Texas Medical Center, Dallas, Texas.
  • Xylinas E; Department of Urology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris Descartes University, Paris, France.
  • Margulis V; Department of Urology, University of Texas Medical Center, Dallas, Texas. Electronic address: Vitaly.margulis@utsouthwestern.edu.
J Urol ; 198(6): 1253-1262, 2017 12.
Article em En | MEDLINE | ID: mdl-28668287
ABSTRACT

PURPOSE:

We investigated the prognostic value of PD-1 and PD-L1 expression in patients with high grade upper tract urothelial carcinoma. MATERIALS AND

METHODS:

Tissue microarrays of 423 patients treated with extirpative surgery for high grade upper tract urothelial carcinoma from the International Upper Tract Urothelial Carcinoma collaboration were stained for PD-1 and PD-L1 using antibodies, including Cell Marque™ NAT105 diluted 1250 and prediluted E1L3N® via immunohistochemistry. A 1% or greater staining rate of tumor infiltrating lymphocytes (PD-1) and tumor cells (PD-L1) was considered positive. Univariate and multivariate analyses were performed to assess independent prognosticators of survival outcomes.

RESULTS:

Median patient age was 70.0 years and median followup was 37.0 months. PD-1 and PD-L1 were positive in 37.2% and 26.2% of patients, respectively. PD-1 positivity was significantly associated with adverse pathological characteristics while PD-L1 positivity was associated with favorable pT stage. On univariate analysis PD-1 expression was associated with worse recurrence-free, cancer specific and overall survival. On multivariate analysis PD-1 expression was an independent prognosticator of cancer specific survival (HR 1.7, 95% CI 1.03-2.66, p = 0.039) and overall survival (HR 1.5, 95% CI 1.05-2.24, p = 0.029) but not recurrence-free survival (HR 1.4, 95% CI 0.9-2.16, p = 0.139). On univariate analysis PD-L1 expression was not significantly associated with survival outcomes. However, on multivariate analysis in patients with organ confined disease (pT2 or less, pN0/x and cM0), PD-L1 positivity was an independent prognosticator of recurrence-free survival (HR 0.2, 95% CI 0.06-0.98, p = 0.046) and overall survival (HR 0.3, 95% CI 0.11-0.63, p = 0.003).

CONCLUSIONS:

PD-1 positivity of tumor-infiltrating lymphocytes was associated with adverse pathological criteria and independent prognostication of worse survival outcomes. PD-L1 positivity of tumor cells was an independent prognosticator of favorable survival outcomes in cases of organ confined disease.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ureterais / Carcinoma de Células de Transição / Antígeno B7-H1 / Receptor de Morte Celular Programada 1 / Neoplasias Renais Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Revista: J Urol Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ureterais / Carcinoma de Células de Transição / Antígeno B7-H1 / Receptor de Morte Celular Programada 1 / Neoplasias Renais Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male Idioma: En Revista: J Urol Ano de publicação: 2017 Tipo de documento: Article